The growth in the historic period can be attributed to high incidence of oral mucositis in chemotherapy, limited effective preventive options, expansion of bone marrow transplantation, clinical validation of kgf therapy, hospital adoption of supportive care drugs.
The growth in the forecast period can be attributed to rising cancer treatment volumes, growth in hematopoietic stem cell transplants, focus on patient quality of life, increasing supportive oncology budgets, advancements in epithelial regeneration therapies. Major trends in the forecast period include rising focus on supportive oncology care, growth in stem cell transplant procedures, increased management of treatment induced mucositis, preference for preventive mucositis therapies, integration of growth factors in oncology protocols.
The increasing prevalence of cancer is expected to propel the growth of the Kepivance market in the future. Cancer, a group of diseases characterized by uncontrolled cell growth and spread, has become more prevalent due to factors such as an aging population, lifestyle factors like poor diet and smoking, better diagnosis and screening techniques, and improved survival rates from advancements in cancer treatments. Kepivance, a medication used to treat mucositis caused by chemotherapy or radiation in cancer patients, alleviates the painful symptoms of oral mucositis, enhancing patients' quality of life and allowing them to continue their cancer treatment. For example, in January 2024, the American Cancer Society reported that the number of cancer cases increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth of 2.19%. This rise in cancer cases is driving the growth of the Kepivance market.
The expansion of healthcare infrastructure is expected to accelerate the growth of the Kepivance market going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, and resources necessary to deliver healthcare services effectively to a population. The expansion of healthcare infrastructure is driven by factors such as population growth, aging populations, the rise in chronic diseases, and the need for more accessible care. As healthcare infrastructure expands, it supports the administration of Kepivance by providing specialized facilities and trained professionals for its intravenous delivery and monitoring during cancer therapy. For instance, in January 2025, according to Sports Medical, a UK-based healthcare industry publication, hospitals remained the dominant segment in UK healthcare construction, accounting for 41% of health project starts in 2024, totaling $2.61 billion (£2bn) - a 9% year-on-year increase. Nursing homes also saw significant growth, accounting for 17% of project starts at $1.07 billion (£822m), reflecting a 25% increase. Therefore, the expansion of healthcare infrastructure is driving the growth of the Kepivance market.
The growing focus on personalized medicine is also expected to boost the Kepivance market. Personalized medicine tailors treatment and healthcare decisions to individual characteristics, needs, and genetic profiles. The increasing demand for personalized medicine is fueled by advancements in genomics, targeted therapies, and the growing prevalence of chronic diseases that require precise treatment approaches. Personalized medicine can enhance the use of Kepivance (palifermin) by optimizing its administration for patients undergoing high-dose chemotherapy and stem cell transplants, based on individual risk factors. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. Among the newly approved treatments were seven cancer drugs. This growing emphasis on personalized medicine is expected to drive the Kepivance market forward.
Major companies operating in the kepivance market are Biovitrum AB.
North America was the largest region in the kepivance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kepivance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kepivance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have impacted the kepivance market by increasing costs related to recombinant protein production inputs, sterile injectable packaging, and cold chain logistics. Oncology treatment centers in north america and europe are most affected due to reliance on imported biologics. These tariffs may increase supportive care therapy costs for hospitals. At the same time, tariffs are encouraging localized biologics manufacturing and strengthening regional supply chains for oncology supportive treatments.
The kepivance market research report is one of a series of new reports that provides kepivance market statistics, including kepivance industry global market size, regional shares, competitors with a kepivance market share, detailed kepivance market segments, market trends and opportunities, and any further data you may need to thrive in the kepivance industry. This kepivance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) designed to stimulate the growth of epithelial cells. It is primarily used to reduce the incidence and severity of oral mucositis in patients undergoing myelotoxic cancer therapy, such as hematopoietic stem cell transplantation. Kepivance helps alleviate pain and improve the quality of life during treatment by promoting the repair and regeneration of the oral mucosa.
The primary indications for Kepivance are the prevention and treatment of oral mucositis. Oral mucositis is a painful condition that often occurs as a side effect of chemotherapy or radiation therapy. Kepivance is available in injectable formulations and lyophilized powders for reconstitution. The routes of administration include intramuscular injection and subcutaneous injection. The product is distributed through various channels such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is used by various end users, including hospitals, oncology clinics, hematology treatment centers, and home healthcare providers.
The kepivance market consists of sales of palifermin-based therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to rising cancer treatment volumes, growth in hematopoietic stem cell transplants, focus on patient quality of life, increasing supportive oncology budgets, advancements in epithelial regeneration therapies. Major trends in the forecast period include rising focus on supportive oncology care, growth in stem cell transplant procedures, increased management of treatment induced mucositis, preference for preventive mucositis therapies, integration of growth factors in oncology protocols.
The increasing prevalence of cancer is expected to propel the growth of the Kepivance market in the future. Cancer, a group of diseases characterized by uncontrolled cell growth and spread, has become more prevalent due to factors such as an aging population, lifestyle factors like poor diet and smoking, better diagnosis and screening techniques, and improved survival rates from advancements in cancer treatments. Kepivance, a medication used to treat mucositis caused by chemotherapy or radiation in cancer patients, alleviates the painful symptoms of oral mucositis, enhancing patients' quality of life and allowing them to continue their cancer treatment. For example, in January 2024, the American Cancer Society reported that the number of cancer cases increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth of 2.19%. This rise in cancer cases is driving the growth of the Kepivance market.
The expansion of healthcare infrastructure is expected to accelerate the growth of the Kepivance market going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, and resources necessary to deliver healthcare services effectively to a population. The expansion of healthcare infrastructure is driven by factors such as population growth, aging populations, the rise in chronic diseases, and the need for more accessible care. As healthcare infrastructure expands, it supports the administration of Kepivance by providing specialized facilities and trained professionals for its intravenous delivery and monitoring during cancer therapy. For instance, in January 2025, according to Sports Medical, a UK-based healthcare industry publication, hospitals remained the dominant segment in UK healthcare construction, accounting for 41% of health project starts in 2024, totaling $2.61 billion (£2bn) - a 9% year-on-year increase. Nursing homes also saw significant growth, accounting for 17% of project starts at $1.07 billion (£822m), reflecting a 25% increase. Therefore, the expansion of healthcare infrastructure is driving the growth of the Kepivance market.
The growing focus on personalized medicine is also expected to boost the Kepivance market. Personalized medicine tailors treatment and healthcare decisions to individual characteristics, needs, and genetic profiles. The increasing demand for personalized medicine is fueled by advancements in genomics, targeted therapies, and the growing prevalence of chronic diseases that require precise treatment approaches. Personalized medicine can enhance the use of Kepivance (palifermin) by optimizing its administration for patients undergoing high-dose chemotherapy and stem cell transplants, based on individual risk factors. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. Among the newly approved treatments were seven cancer drugs. This growing emphasis on personalized medicine is expected to drive the Kepivance market forward.
Major companies operating in the kepivance market are Biovitrum AB.
North America was the largest region in the kepivance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kepivance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kepivance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have impacted the kepivance market by increasing costs related to recombinant protein production inputs, sterile injectable packaging, and cold chain logistics. Oncology treatment centers in north america and europe are most affected due to reliance on imported biologics. These tariffs may increase supportive care therapy costs for hospitals. At the same time, tariffs are encouraging localized biologics manufacturing and strengthening regional supply chains for oncology supportive treatments.
The kepivance market research report is one of a series of new reports that provides kepivance market statistics, including kepivance industry global market size, regional shares, competitors with a kepivance market share, detailed kepivance market segments, market trends and opportunities, and any further data you may need to thrive in the kepivance industry. This kepivance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) designed to stimulate the growth of epithelial cells. It is primarily used to reduce the incidence and severity of oral mucositis in patients undergoing myelotoxic cancer therapy, such as hematopoietic stem cell transplantation. Kepivance helps alleviate pain and improve the quality of life during treatment by promoting the repair and regeneration of the oral mucosa.
The primary indications for Kepivance are the prevention and treatment of oral mucositis. Oral mucositis is a painful condition that often occurs as a side effect of chemotherapy or radiation therapy. Kepivance is available in injectable formulations and lyophilized powders for reconstitution. The routes of administration include intramuscular injection and subcutaneous injection. The product is distributed through various channels such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is used by various end users, including hospitals, oncology clinics, hematology treatment centers, and home healthcare providers.
The kepivance market consists of sales of palifermin-based therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Kepivance Market Characteristics
3. Kepivance Market Supply Chain Analysis
4. Global Kepivance Market Trends and Strategies
5. Kepivance Market Analysis of End Use Industries
7. Global Kepivance Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Kepivance Total Addressable Market (TAM) Analysis for the Market
9. Kepivance Market Segmentation
10. Kepivance Market Regional and Country Analysis
11. Asia-Pacific Kepivance Market
12. China Kepivance Market
13. India Kepivance Market
14. Japan Kepivance Market
15. Australia Kepivance Market
16. South Korea Kepivance Market
17. Western Europe Kepivance Market
18. UK Kepivance Market
19. Germany Kepivance Market
20. France Kepivance Market
21. Eastern Europe Kepivance Market
22. North America Kepivance Market
23. USA Kepivance Market
24. Canada Kepivance Market
25. South America Kepivance Market
26. Middle East Kepivance Market
27. Africa Kepivance Market
29. Kepivance Market Competitive Landscape and Company Profiles
32. Kepivance Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Kepivance Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses kepivance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kepivance? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The kepivance market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Prevention Of Oral Mucositis; Treatment Of Oral Mucositis2) By Formulation: Injectable Formulation; Lyophilized Powder For Reconstitution
3) By Route Of Administration: Intramuscular Injection; Subcutaneous Injection
4) By Distribution Channel: Direct Sales; Wholesalers And Distributor; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Oncology Clinics; Hematology Treatment Centers; Home Healthcare Providers
Companies Mentioned: Biovitrum AB
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Kepivance market report include:- Biovitrum AB
